We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 130

Snapshot of Sunshine rules in EU countries for the pharmaceutical industry part 1 - June 2014
  • McDermott Will & Emery
  • European Union, United Kingdom
  • June 12 2014

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. In 2013

The New EU Regulation on Medical Devices Aims at Enhanced Product Safety and Further Harmonization
  • McDermott Will & Emery
  • European Union, USA
  • May 9 2017

On May 5, 2017, the new Regulation on Medical Devices (MDR) and the new Regulation on In Vitro Diagnostics (IVDR) were published in the European

EC introduces major changes to medical device regulation
  • McDermott Will & Emery
  • European Union
  • December 17 2012

The European Commission has issued two proposals that, if approved, will fundamentally amend EU law on medical devices and in vitro diagnostics

Repackaging and parallel import of pharmaceutical products
  • McDermott Will & Emery
  • European Union
  • May 22 2007

On 27 April 2007, the European Court of Justice (the “ECJ”) handed down yet another decision in the case of Boehringer Ingelheim & others v Swingward Ltd and Dowelhurst Ltd, Case C-34804 (“Boehringer II”

Controlling and processing data in EU clinical trials
  • McDermott Will & Emery
  • European Union
  • November 22 2010

The legal regime for the conduct of clinical trials of medicinal products for human use in the European Union is set out in Directive 200120EC (the Clinical Trials Directive

The case of ophthalmic drugs in Italy and France: a lesson to learn - parallel antitrust investigations and cooperation between national competition authorities
  • McDermott Will & Emery
  • European Union, France, Italy
  • May 7 2014

The recent investigations into two pharmaceutical companies active in the ophthalmic drugs market in Italy and France serve as a reminder of the

EPO Enlarged Board of Appeal invites the public to determine whether stem cells are contrary to morality
  • McDermott Will & Emery
  • European Union
  • July 30 2008

On 24 and 25 June 2008, in a public hearing on Wisconsin Alumni Research Foundation (WARF) Stem Cell patent application (G-0206), the European Patent Office (EPO) took the usual step of asking the public to assist it in making a determination regarding a patent application involving an invention in the controversial area of stem cell patenting

EU Court Confirms European Commission’s Decision on Pay-for-Delay Agreements
  • McDermott Will & Emery
  • Denmark, European Union
  • October 20 2016

On 8 September 2016, the General Court of the European Union upheld the European Commission’s decision in which the antitrust regulator imposed fines

Commission dawn-raids pharmaceutical companies on eve of sector report
  • McDermott Will & Emery
  • European Union
  • November 28 2008

The European Commission has confirmed that on 24 November 2008, Commission officials started inspections at the premises of a number of pharmaceutical companies in several EU Member States

Commission investigates pharmaceutical sector for anti-competitive practices
  • McDermott Will & Emery
  • European Union
  • January 18 2008

The European Commission has launched a sector inquiry with a series of on-the-spot competition investigations into pharmaceutical companies